相似文献
1
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Br J Pharmacol. 2007 Mar;150(5):538-40. doi: 10.1038/sj.bjp.0707132. Epub 2007 Jan 22.
2
Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.
Br J Pharmacol. 2007 Mar;150(5):567-76. doi: 10.1038/sj.bjp.0707131. Epub 2007 Jan 22.
3
Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Ann Thorac Surg. 2006 Jan;81(1):272-8. doi: 10.1016/j.athoracsur.2005.06.040.
4
Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Circulation. 2004 Nov 9;110(19):3149-55. doi: 10.1161/01.CIR.0000146906.42375.D3.
5
Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Curr Hypertens Rep. 2006 Aug;8(4):345-51. doi: 10.1007/s11906-006-0075-y.
6
Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Clin Exp Pharmacol Physiol. 2009 Apr;36(4):358-66. doi: 10.1111/j.1440-1681.2008.05071.x. Epub 2008 Oct 15.
7
In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach.
Urol Res. 2007 Feb;35(1):49-54. doi: 10.1007/s00240-006-0073-1. Epub 2006 Nov 11.
8
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Adv Ther. 2009 Sep;26(9):813-25. doi: 10.1007/s12325-009-0064-z. Epub 2009 Sep 19.
9
Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Cardiol Rev. 2007 Mar-Apr;15(2):76-86. doi: 10.1097/01.crd.0000233904.77128.49.
10
New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
J R Soc Promot Health. 2003 Jun;123(2):79-80. doi: 10.1177/146642400312300209.
引用本文的文献
1
OTUD1 deficiency attenuates myocardial ischemia/reperfusion induced cardiomyocyte apoptosis by regulating RACK1 phosphorylation.
Acta Pharmacol Sin. 2025 May 20. doi: 10.1038/s41401-025-01567-x.
2
Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives.
Pharmaceuticals (Basel). 2023 Sep 6;16(9):1266. doi: 10.3390/ph16091266.
3
Updates on Pharmacologic Management of Microvascular Angina.
Cardiovasc Ther. 2022 Oct 25;2022:6080258. doi: 10.1155/2022/6080258. eCollection 2022.
4
Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy.
Inflammation. 2016 Jun;39(3):1238-52. doi: 10.1007/s10753-016-0359-6.
5
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications.
J Endocrinol Invest. 2016 Feb;39(2):143-51. doi: 10.1007/s40618-015-0340-5. Epub 2015 Jun 28.
6
Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials.
BMC Med. 2014 Oct 20;12:185. doi: 10.1186/s12916-014-0185-3.
7
KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin.
Kaohsiung J Med Sci. 2012 Nov;28(11):567-76. doi: 10.1016/j.kjms.2012.04.022. Epub 2012 Jul 25.
8
Effects of sildenafil and/or muscle derived stem cells on myocardial infarction.
J Transl Med. 2012 Aug 7;10:159. doi: 10.1186/1479-5876-10-159.
9
Systemic and metabolic effects of PDE5-inhibitor drugs.
World J Diabetes. 2010 Mar 15;1(1):3-7. doi: 10.4239/wjd.v1.i1.3.
10
Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta.
J Biol Chem. 2008 Oct 24;283(43):29572-85. doi: 10.1074/jbc.M801547200. Epub 2008 Aug 21.
本文引用的文献
1
Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat.
Br J Pharmacol. 2007 Mar;150(5):567-76. doi: 10.1038/sj.bjp.0707131. Epub 2007 Jan 22.
2
Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits.
J Mol Cell Cardiol. 2007 Feb;42(2):453-8. doi: 10.1016/j.yjmcc.2006.10.015. Epub 2006 Dec 8.
3
Cyclic GMP-dependent protein kinase Ialpha attenuates necrosis and apoptosis following ischemia/reoxygenation in adult cardiomyocyte.
J Biol Chem. 2006 Dec 15;281(50):38644-52. doi: 10.1074/jbc.M606142200. Epub 2006 Oct 12.
4
Effect of regular phosphodiesterase type 5 inhibition in hypertension.
Hypertension. 2006 Oct;48(4):622-7. doi: 10.1161/01.HYP.0000239816.13007.c9. Epub 2006 Aug 28.
5
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.
Nat Rev Drug Discov. 2006 Aug;5(8):689-702. doi: 10.1038/nrd2030.
6
The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size.
Int J Impot Res. 2007 Jan-Feb;19(1):55-61. doi: 10.1038/sj.ijir.3901497. Epub 2006 Jul 20.
7
Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits.
J Mol Cell Cardiol. 2006 Mar;40(3):405-11. doi: 10.1016/j.yjmcc.2005.10.002. Epub 2006 Feb 9.
8
Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications.
Vascul Pharmacol. 2005 Apr-May;42(5-6):219-32. doi: 10.1016/j.vph.2005.02.010. Epub 2005 Mar 29.
9
Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity.
Circulation. 2005 Apr 5;111(13):1601-10. doi: 10.1161/01.CIR.0000160359.49478.C2.
10
Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study.
Circulation. 2005 Feb 15;111(6):742-6. doi: 10.1161/01.CIR.0000155252.23933.2D. Epub 2005 Feb 7.
Zotero 插件